Login
← Go Back
Glenmark Pharmaceuticals
GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com
Stock Price vs Company Growth
1d
3.9%
1w
2.1%
1m
6.5%
3m
3.3%
6m
2.0%
1y
53.4%
5y
34.4%
10y
10.1%
all
10.8%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 2,040 3.9%
1,843
2,160
Company Overview
Sales
16,468 Cr
Growth: 29.9%
Profit after Tax
1,065 Cr
Growth: 5.5%
Large Cap
57,572 Cr
P/E: 54.1x
Industry P/E: 27.8x
Fundamentals
Sales (Cr) ₹ 16,468
Growth 29.9%
EBITDA 26.5%
P/S 3.5x
Dividend 0.1%
P/E 54.1x
Book Value ₹ 351
PEG Ratio 1.8x
ROE 11.5%
P/B 5.8x
Shareholding Pattern
Institutions
Qualified Institutional Buyer
4.74 %
Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac
3.25 %
Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund
2.26 %
Ntasain Discovery Master Fund
2.05 %
Life Insurance Corporation Of India
1.76 %
Promoters
Saldanha Family Trust
45.45 %
Blanche Elizabeth Saldanha
0.39 %
Glenn Mario Saldanha
0.35 %
Cherylann Maria Pinto
0.27 %
Robin Joseph Pinto
0.18 %
Others
Ashish Dhawan
1.81 %
Iepf
0.08 %
Increase    Decrease    No change
Company Profile Detailed
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products.
Belongs to (40 Indices) view more
Investors (111)
general....
credit.s...
tata.bal...
Followers (37)
nitin2
keerthi
deepak